tbuckley/cabot-search huggingface dataset:
M14 A multi-site online cross-sectional survey assessing influenza vaccination uptake among london medical students and modifiable factors influencing this
Authors: GA Pankin, NE Jackson, IS Patel, AS Patel
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Around 1 in 5 healthcare workers (HCWs) may become infected during the influenza (flu) season and between 28–59% will have subclinical illness which they could pass on to those more vulnerable. As a result, annual vaccination against flu is recommended for all UK National Health Service staff. However, during the 2015/16 season only 55% of HCWs with direct clinical roles were vaccinated, with lower than average rates seen in London. Like any HCW, medical students should be actively encouraged to get vaccinated. Our aim was to assess levels of flu vaccine uptake among London medical students and investigate the negative influences affecting uptake that could be addressed at an institutional level. <h3>Methods</h3> A cross-sectional online survey, developed by a focus group of respiratory consultants and medical students, was disseminated to London medical students at King’s College Hospital, Guy’s and St Thomas’ Hospitals and University Hospital Lewisham. Data was collected and analysed using SurveyMonkey Inc. <h3>Results</h3> 302 medical students completed the survey (Table 1). There was a good representation of students across different sites and clinical years. Overall, 44% students reported receiving the flu vaccine. Uptake varied between teaching sites and clinical years. 82% of students felt they should get vaccinated with 51% of those doing so. 64% of those who were not vaccinated said they were not offered it, of whom 73% felt vaccination was appropriate. 50% of all students said they were not provided with any information about the vaccine. 68% of those who were provided with information were vaccinated whereas 20% of those who were not provided with information were vaccinated. <h3>Conclusions</h3> Vaccination rates among London medical students are lower than for most HCWs. There appears to be a discrepancy between willingess to get vaccinated and actual uptake rates. This may be due to a lack of information and encouragement rather than a lack of access, as 72% of all students were aware of how to access the vaccine. Teaching hospitals and the University should address this by introducing flu vaccination awareness into the curriculum and consider adding it to mandated occupation health assessments.
P3.02c-035 Comparison of RECIST to Immune-Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune-Check Point Inhibitor
Authors: Hee Kyung Kim, Hansang Lee, Mi Hwa Heo, Jinhyun Cho, Ju Youn Park, Su-Mi Jeong, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park
Journal: Journal of Thoracic Oncology (2017)
P211 Using the clinical practice research datalink (CPRD) to recruit participants from primary care to investigate chronic obstructive pulmonary disease (COPD) exacerbations
Authors: E Moore, M Hashmi, K Sultana, L Chatzidiakou, RL Jones, S Beevers, FJ Kelly, L Smeeth, B Barratt, M Wright, JK Quint
Journal: Thorax (2016)

<h3>Introduction</h3> Traditionally, recruitment for health research involves clinicians identifying and then contacting potentially suitable participants. This can be both time-consuming and labour intensive for clinicians and researchers. Databases of Electronic Healthcare Records (EHRs) can be used as a resource through which potential study participants can be approached but is often underutilised in spite of previously being shown to be effective (Horspool <i>et al</i>, 2013). For a study investigating the association between air pollution and COPD exacerbations using portable air monitors and symptom diaries, we employed a relatively novel method of recruitment involving approaching patients to participate via the Clinical Practice Research Datalink (CPRD), an anonymised general practitioner (GP) records database containing ongoing primary care medical data. <h3>Methods</h3> Patients registered at general practices within Greater London whose GP practices were part of the CPRD network were identified anonymously by CPRD using a validated codelist and algorithm developed by our team (Quint <i>et al</i>, 2014). GPs were able to verify the suitability of the potential participants identified and post information about the study to them. Patients could register their interest in the study directly with the research team to be enrolled in the study. <h3>Results</h3> Feasibility screening by CPRD between January and July 2016 indicated 675 potential study participants at 20 practices and from the CPRD-supplied practice screening lists GPs identified and deemed eligible 462 patients. 462 patients were contacted and the response rate was 136/462 of which 43 (32%) were enrolled and 93 (68%) declined. The main reason for declining was related to the demands that the project entailed of looking after the air monitor and diary for 6 months. <h3>Conclusion</h3> Patients with COPD from GP practices within Greater London were successfully screened and recruited through CPRD to participate in research over a 6 month period thus providing access to a milder cohort of research naive patients who better represent the majority of the COPD population and this method minimised input needed by the GP. This is a novel method of using EHRs to recruit participants for research that is currently underutilised.
Intra-Bone Marrow Transplantation of CD34+ Enriched Grafts Following a Non-Myeloablative Conditioning Allows Successful Engraftment In DLA-Identical Canine Litters.
Authors: Anne Knueppel, Doreen Killian, Sandra Lange, Heike Vogel, Iris Lindner, Simone Dunkelmann, Friedrich Prall, Mathias Freund, Gudrun Knuebel, Anett Sekora, Christian Junghanss
Journal: Blood (2010)
P1.07-003 A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC
Authors: Christian Grohé, Walburga Engel-Riedel, Cornelia Kropf-Sanchen, Von Pawel Joachim, Sylvia Gütz, Jens Kollmeier, Wilfried Eberhardt, Petros Christopoulos, Inko Nimmrich, Christian Sieder, Volker Baum, Monika Serke, Michael Thomas
Journal: Journal of Thoracic Oncology (2017)
Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis
Authors: Nyasha Chambwe, Matthias Kormaksson, Subhajyoti De, Franziska Michor, Nathalie Johnson, David W Scott, Randy D. Gascoyne, Ari Melnick, Fabien Campagne, Rita Shaknovich
Journal: Blood (2011)
P1.08-066 Prognostic Factors of Post-Recurrence Survival in Patients with Completely Resected Stage III-N2 Non-Small Cell Lung Cancer
Authors: Kyung Wook Shin, Sukki Cho, Sung Won Yum, Hyo-Jun Jang, Kwhanmien Kim, Sanghoon Jheon
Journal: Journal of Thoracic Oncology (2017)
Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc−/− Xenograft and Confer Susceptibility to Cytarabine
Authors: Sylvia Chien, Xin Zhao, John T. Patton, Theodore Smith, Arun Sarkar, John L. Magnani, Frederick R. Appelbaum, Pamela S Becker
Journal: Blood (2011)
P2.04-012 A Risk of Death from a Second Cancer Following Complete Resection of Thymoma
Authors: Masatsugu Hamaji, Kyoko Hijiya, Hideki Motoyama, Toshi Menju, Akihiro Aoyama, Toshihiko Sato, Fengshi Chen, Makoto Sonobe, Hiroshi Date
Journal: Journal of Thoracic Oncology (2017)
P2.03b-019 Comparison of the Efficacy of First-Generation EGFR-TKIs in Brain Metastasis
Authors: Naoto Aiko, Tsuneo Shimokawa, Kazuhito Miyazaki, Yuki Misumi, Akira Sato, Yoko Agemi, Mari Ishii, Yukiko Nakamura, Hiroaki Okamoto
Journal: Journal of Thoracic Oncology (2017)
Clinical relevance of proteolytic activity imbalance in breast cancer.
Authors: F. D. Shah, S. N. Shukla, P. S. Patel
Journal: Journal of Clinical Oncology (2011)

e21043 Background: Invasion and metastasis, the most dangerous and life threatening feature for breast cancer result due to changes in many molecular events, including the imbalance of proteolytic activity. Therefore we evaluated expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in 70 controls, 70 patients with benign breast disease (BBD) and 125 breast cancer patients (BCPT) as well as 93 posttreatment follow-up samples. Methods: Blood samples from all the subjects and malignant, adjacent normal, positive and negative lymphnode tissues from the patients were collected. Expression of MMP-2 and MMP-9 were examined from tissues using zymography. ELISA was carried out to evaluate levels of MMPs and TIMPs. Results: Malignant tissues showed higher active MMP-2 and MMP-9 levels. Activation ratios of MMP-2 and MMP-9 were significantly higher in malignant tissues and in patients with lymphnode metastasis. Receivers operating characteristic (ROC) curve showed proMMP-2, active MMP-2, and active MMP-9 could significantly discriminate between malignant and adjacent normal tissues and MMP-2 activation ratio could significantly discriminate between patients with and without lymph node metastasis. Odds ratio analysis suggested MMP-2 activation ratio have significant association with increased risk of lymph node metastasis in node-negative patients. Plasma MMP-2 and TIMP-1 levels were significantly lower and MMP-9 and TIMP-2 were significantly higher in BCPT compared to controls. Plasma MMPs and TIMP levels were also altered in BBD. Plasma MMP-2 and MMP-9 could significantly discriminate between controls and BCPT. Multiple molecular approach using mROC analysis revealed significantly improved sensitivity and specificity. Serial evaluation of plasma MMP-2, MMP-9, TIMP-1 and TIMP-2 could correlate with disease status and can be useful for treatment monitoring of the BCPT. Conclusions: The results suggested that TIMPs functions in MMP dependent manner in breast cancer and are important in tumor invasion and metastasis. The follow-up analysis of MMP-2, MMP-9, TIMP-1 and TIMP-2 suggested that MMP-2, MMP-9 and TIMP-1 can be used as treatment monitors for breast cancer patients.
Diagnostic utility of digital cholangioscopy for dislodged bile duct tumor thrombus of hepatocellular carcinoma
Authors: Tadahisa Inoue, Tomohiko Ohashi, Yukiomi Nakade, Yuji Kobayashi, Norimitsu Ishii, Kiyoaki Ito, Masashi Yoneda
Journal: Endoscopy (2017)

Bile duct tumor thrombus (BDTT) of hepatocellular carcinoma (HCC) is rare, and making a differential diagnosis from bile duct cancer is often challenging [1]. We present a rare case of HCC with BDTT mimicking hilar bile duct cancer, which could be diagnosed by a new digital cholangioscopy system (SpyGlass DS; Boston Scientific Corp., Marlborough, Massachusetts, USA) [2].
Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group
Authors: Stefanie Kreissl, Helen Goergen, Bastian von Tresckow, Karolin Behringer, Jana Markova, Andreas Lohri, Julia Meissner, Josée M Zijlstra, Richard Greil, Max S. Topp, Martin Sökler, Hartmut Döhner, Volker Diehl, Andreas Engert, Peter Borchmann
Journal: Blood (2015)
Maternal Embryonic Leucine Zipper Kinase (MELK) Drives a High-Risk Gene Network and Represents an Attractive Novel Drug Target in Multiple Myeloma
Authors: Arnold Bolomsky, Roy Heusschen, Karin Schlangen, Kathrin Schönfelder, Joséphine Muller, Wolfgang Schreiner, Niklas Zojer, Jo Caers, Heinz Ludwig
Journal: Blood (2016)
KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia
Authors: Fida Khater, Mathieu Lajoie, Sylvie Langlois, Jasmine Healy, Sonia Cellot, Chantal Richer, Patrick Beaulieu, Pascal St-Onge, Virginie Saillour, Mark Minden, Monia Marzouki, Maja Krajinovic, Henrique Bittencourt, Daniel Sinnett
Journal: Blood (2017)
ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category
Authors: Klaus H. Metzeler, Heiko Becker, Kati Maharry, Michael D. Radmacher, Jessica Kohlschmidt, Krzysztof Mrózek, Deedra Nicolet, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Bayard L. Powell, Thomas H. Carter, Meir Wetzler, Joseph O. Moore, Jonathan E. Kolitz, Maria R. Baer, Andrew J. Carroll, Richard A. Larson, Michael A Caligiuri, Guido Marcucci, Clara D. Bloomfield
Journal: Blood (2011)
Adding docetaxel and mitomycin-C to low-dose multidrug therapy for pancreatic cancer.
Authors: A. Hirschfeld, J. Stega, S. Buddaraju, M. Jahan, H. Bruckner
Journal: Journal of Clinical Oncology (2011)

e14545 Background: Gemcitabine, fluorouracil, leucovorin, irinotecan, cisplatin, (GFLIP) and GFLIP + docetaxel (GFLIP-TXT) are effective in sequence for the treatment of pancreatic cancer. (Bruckner et al ASCO 2008) These regimens demonstrate that adding a selected new drug to a failed multi-drug core regimen can yield a significant rate of benefit as shown for irinotecan, methotrexate and docetaxel (Bruckner et al ASCO 2001, 2004, 2008) . A new drug addition can produce potentially synergistic drug pairs with each of the failed core drugs, and can reverse drug resistance. The MZB in-vitro assay finds mitomycin-C (MMC) often synergistic with the individual core drugs of GFLIP-TXT in tumors resistant to the individual drugs. Methods: This is a retrospective review of 40 patients with unresectable or recurrent pancreatic cancer failing GFLIP or gemcitabine, fluorouracil, leucovorin, irinotecan, and oxaliplatin (GFLIOx) who were treated with added docetaxel (TXT) 25 mg/m2 with or without MMC 4-6 mg/m2, maximum 10 mg, q2weeks, added to GFLIP/Ox at 80% of the failed prior well tolerated dosage. All patients had measurable disease and had recovered from prior GFLIP/Ox nadir events. MMC was used based on acuity, threatening symptoms and “need” for urgent response. TXT was added alone for asymptomatic radiology confirmed progression of disease. Results: Interim review found that patients treated with this sequence produced an overall median survival of 16+ months. Adding TXT and MMC to GFLIP/Ox on progression produced a secondary median survival of 7 months from first use of the added drugs. There were no febrile neutropenic episodes or bleeding due to treatment in the reviewed group. Full results comparing TXT with and without MMC will be available in April 2011. Conclusions: Adding TXT and MMC to GFLIP/Ox is a feasible second line option for patients with refractory pancreatic cancer. These data further support the paradigm that drug repartnering can give a failed drug or regimen a second chance.
S48 Targeting siglecs to reduce protease-mediated destruction in tuberculosis
Authors: W Beynon, R McMullan, D McAuley, C O’Kane
Journal: Thorax (2016)

<h3>Background</h3> Tuberculosis (TB) is an inflammatory disease caused by infection with <i>Mycobacterium tuberculosis</i> (Mtb). The disease is often characterised by destructive pulmonary pathology, which itself aids transmission, and many who complete otherwise successful treatment are left with lasting respiratory impairment following TB-driven tissue damage and remodelling. This is largely mediated by matrix metalloproteinases (MMP) induced in the inflammatory response. The CD33-related siglecs are transmembrane receptors that bind sialic acid. They are selectively expressed on immune cells, where they mediate inhibitory signalling. Murine Siglec-E is upregulated on macrophages by LPS. Its activation by crosslinking with sialylated nanoparticles reduces inflammatory cytokine release and mortality in murine models of sepsis and lung injury. Siglecs −5, −7 and −9 are candidate human orthologs of Siglec-E, known to inhibit inflammatory cell activation and proliferation. We hypothesised that the human orthologs of Siglec-E are upregulated in response to Mtb, which like LPS is a TLR-4 ligand, and that their activation would reduce TB-driven inflammation. <h3>Methods</h3> Siglec expression at gene and protein level on primary monocytes isolated from blood donation, and in a monocyte derived macrophage (MDM) model was investigated by qPCR, flow cytometry and western blotting in both unstimulated and Mtb-infected cells. Monocytes and MDMs were infected with Mtb and incubated with antibodies to either neutralise or crosslink siglecs -7 and -9. The effect on their secretion of inflammatory cytokines and MMPs or their inhibitors (Tissue Inhibitors of Metalloproteinases – TIMPs) was measured by ELISA. <h3>Results</h3> Siglecs -5, -7 and -9 are constitutively expressed on human monocytes and MDMs. Unlike Siglec-E in mice, these siglecs are not upregulated by LPS stimulation, nor by infection with Mtb. Blocking the functions of Siglec-7 and -9 on both primary monocytes and MDM with neutralising antibodies does not alter the<i> in vitro </i>inflammatory response to Mtb. Antibody crosslinking Siglec-9, but not Siglec-7, on MDMs induces endogenous MMP inhibitor TIMP1 (p = 0.001, see figure 1), lowering the MMP9/TIMP1 ratio which is a predictor of proteolytic damage. <h3>Conclusion</h3> Crosslinking Siglec-9 on MDMs has potential to reduce their net proteolytic activity in Mtb infection and may reduce harmful tissue damage.
P2.01-063 PDL1, JAK2 and PTEN Copy Number Alterations Synergistically Upregulate PD-L1 Expression in NSCLC
Authors: Sergi Clavé, Lara Pijuan, David Casadevall, Álvaro Taus, María Rodríguez-Rivera, Sílvia Menéndez, Joan Albanell, Blanca Espinet, Edurne Arriola, Marta Salido
Journal: Journal of Thoracic Oncology (2017)
Eyebrow and Eyelash Loss
Authors: Jules B. Lipoff, Katherine T. Steele, Neha Jariwala
Journal: JAMA (2017)

A 41-year-old man who had immigrated from Costa Rica 10 years prior presented with paresthesias in his hands and feet, loss of the eyebrows and eyelashes, and skin changes including mild erythema of the earlobes, fingers, and toes. He reported taking no medications. What would you do next?
A HUMAN MODEL OF INTRA-ABDOMINAL HYPERTENSION: EVEN SLIGHTLY ELEVATED PRESSURES LEAD TO INCREASED ACUTE SYSTEMIC INFLAMMATION AND SIGNS OF ACUTE KIDNEY INJURY
Authors: Marije Smit, H. S. Hofker, H. G. D. Leuvenink, C. Krikke, R. M. Jongman, J. G. Zijlstra, M. van Meurs
Journal: Intensive Care Medicine (2013)
P253 Could application of simple diagnostic algorithm aid onward referral for optimisation of pre-existing conditions in patients being considered for major surgery?
Authors: J Hornsby, P Higgins, A Baker, E Black, D Anderson
Journal: Thorax (2016)

<h3>Introduction</h3> Cardiopulmonary exercise testing (CPET) is used to identify physiological limitation to exercise and aid diagnosis of cardiorespiratory, psychological and muscle disorders.<sup>1</sup> It is also frequently used to stratify operative risk thereby aiding decision making in patients considered for major surgical procedures.<sup>2</sup> The evidence for risk stratification is based on the oxygen consumption at anaerobic threshold (VO<sub>2</sub> AT) along with metabolic equivalence.<sup>2</sup> Attention is therefore generally paid to the numerical value of these measures rather than full interpretation of the data. Further interpretation may allow further diagnosis and optimisation of pre-existing conditions. <h3>Methods</h3> We retrospectively applied a simple diagnostic algorithm (Figure 1) to CPETs undertaken by patients considered for major surgery in the Victoria Infirmary, Glasgow between 2014–2016. <h3>Results</h3> The records of 39 patients who had a pre-operative CPET testing were analysed: 22 male, 17 female, age range 43–88, median 73.A total of 26 patients were classified as high risk, 23 achieved an AT &lt;11 mls/kg/min and 3 with a metabolic equivalent &lt;4.0mls0<sub>2</sub>/kg/min. Both parameters were low in 13 patients. Ten patients had their procedures cancelled due to this. Eleven high risk patients had a normal VO<sub>2</sub> max. Upon applying the diagnostic algorithm; 15 patients were deconditioned, 6 had cardiovascular limitation, 3 had respiratory limitation and 15 were normal. In the ‘high risk’ population: 2 patients had respiratory limitation with pre-existing respiratory conditions and were cancelled. Six patients had cardiovascular limitation with 3 patients having pre-existing cardiac diagnosis, 3 were cancelled. Seven of the patients were ‘deconditioned’; 5 were cancelled as a result. <h3>Conclusion</h3> This algorithm suggests that 8 patients were considered high risk as a result of cardiorespiratory disease and a further 7 as a result of deconditioning. Appropriate speciality review and intervention or an exercise prescription pre-operatively might allow patients to improve their operative risk and therefore to proceed to major surgery. <h3>References</h3> Cooper C, Storer T. <i>Exercise testing and interpretation. A practical approach</i>. Edinburgh: Cambridge University Press, 2001. Moran J, <i>et al</i>. Role of cardiopulmonary exercise testing as a risk-assessment method in patients undergoing intra-abdominal surgery: a systematic review. <i>BJA</i> 2016;<b>116</b>(2):177–191.
Decitabine Is Effective In Patients with Myelodysplastic Syndromes Who Failed Prior Intensive Regimen: No Negative Impact of Prior Therapy
Authors: Elias Jabbour, Hagop Kantarjian, Tapan Kadia, Gautam Borthakur, Jorge E. Cortes, A. Megan Cornelison, Farhad Ravandi, Guillermo Garcia-Manero
Journal: Blood (2010)
P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant
Authors: Kelvin Young, Max Marquez, Jonathan Yeung, Frances Shepherd, Shaf Keshavjee, Eberhard Renner, Joseph Kim, Heather Ross, Tim Aliev, Geoffrey Liu, Natasha Leighl, Ronald Feld, Penelope Bradbury
Journal: Journal of Thoracic Oncology (2017)
Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL
Authors: Matthew S. Davids, Haesook T. Kim, Elizabeth Gilbert, Leslie Cowen, Karen Francoeur, Jeffrey Hellman, Jon E. Arnason, David C. Fisher, Jennifer R. Brown
Journal: Blood (2015)
LONG TERM FOLLOW-UP RESULTS OF EORTC 26951: A RANDOMIZED PHASE III STUDY ON ADJUVANT PCV CHEMOTHERAPY IN ANAPLASTIC OLIGODENDROGLIAL TUMORS - A REPORT OF THE EORTC BRAIN TUMOR GROUP
Authors: M. J. van den Bent, A. A. Brandes, M. J. B. Taphoorn, J. M. Kros, M. Kouwenhoven, J. Y. Delattre, H. J. J. A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, R. H. Enting, P. J. French, W. N. M. Dinjens, C. J. Vecht, A. Allgeier, D. Lacombe, T. Gorlia, K. Hoang Xuan
Journal: Neuro-Oncology (2012)